Need more? Try out  Advanced Search (20+ criteria)»

logo

Last Update

This profile was last updated on 6/12/2017 and contains contributions from the  Zoominfo Community.

is this you? Claim your profile.

Wrong Jag Khalsa?

Jag H. Khalsa

Clinical Evaluator

Food and Drug Administration

HQ Phone:  (888) 463-6332

Email: k***@***.gov

GET ZOOMINFO GROW

+ Get 10 Free Contacts a Month

Please agree to the terms and conditions.

I agree to the  Terms of Service and  Privacy Policy. I understand that I will receive a subscription to ZoomInfo Grow at no charge in exchange for downloading and installing the ZoomInfo Contact Contributor utility which, among other features, involves sharing my business contacts as well as headers and signature blocks from emails that I receive.

THANK YOU FOR DOWNLOADING!

computers
  • 1.Download
    ZoomInfo Grow
    v sign
  • 2.Run Installation
    Wizard
  • 3.Check your inbox to
    Sign in to ZoomInfo Grow

I agree to the Terms of Service and Privacy Policy. I understand that I will receive a subscription to ZoomInfo Community Edition at no charge in exchange for downloading and installing the ZoomInfo Contact Contributor utility which, among other features, involves sharing my business contacts as well as headers and signature blocks from emails that I receive.

Food and Drug Administration

10903 New Hampshire Ave

Silver Spring, Maryland,20993

United States

Company Description

China's Food and Drug Administration (SFDA) is now offering a reward of about 50,000 US dollars for relevant information on counterfeit drug production. The bounty aims to "encourage the public to report illegal activities so as to determine, control and elimi...more

Background Information

Employment History

Chief, Medical Consequences of Drug Abuse and Infections

National Institutes of Health


Chief, Medical Consequences Branch, Division of Pharmacotherapies and Medical Consequences of Drug Abuse

National Institute on Drug Abuse, NIH


Chief, Medical Consequences of Drug Abuse and Infections

US National Institutes of Health


Affiliations

HHS Viral Hepatitis Implementation Group

Numerous Federal and NIH Level Committees


Education

Master's degree

herbal pharmacology


Ph.D.

National Institute


Ph.D.

neuro-psycho-pharmacology

SK&F


PhD

Harvard Medical School


Web References(35 Total References)


Editorial Board Members | USG

blumsrewarddeficiencysyndrome.com [cached]

Dr. Jag Khalsa, with about 50 years of experience in drug research, serves as the Chief of the Medical Consequences Branch, National Institute on Drug Abuse, NIH, DHHS; is responsible for developing/administering a national and international program of clinical research on medical and health consequences of drug abuse and co-occurring infections (HIV, HCV, and others).
Prior to joining NIDA in 1987, he served for ~10 yrs as a pharmacologist/toxicologist assessing safety (carcinogenic/teratogenic) potential of chemicals [INDs/NDAs] and food additives) and clinical evaluator at FDA. He has published in pharmacology, toxicology, epidemiology and medical journals. He serves on editorial boards of Journals of Addiction Medicine, Research on HIV/AIDS and Palliative Care, Frontiers of Neuroscience, and Clinical Infectious Diseases. He also serves on numerous Federal and NIH level committees including the HHS Viral Hepatitis Implementation Group (VHIG), National Commission on Digestive Diseases and its two sub-committees (Liver Research, Diabetes Research), Federal Task Force on TB, NIH Steering Committee on Centers for AIDS Research, and Human Microbiome Workgroup. He has received distinguished service awards from the FDA Commissioner, NIDA and NIH Directors, Society of Neuro-Immune-Pharmacology (SNIP), Life Time Achievement Awards from SNIP and International Conference on Molecular Medicine (India) and MIT, India; a commendation from the US Congress, Awards of Merit from the International Society of Addiction Medicine (ISAM), the President of the American Society of Addiction Medicine (ASAM), and a Certificate of Appreciation from the Office of Assistant Secretary for Health (Drs. Howard Koh and Ron Valdiserri), DHHS. He has a PhD in neuro-psycho-pharmacology, a Master's degree in herbal pharmacology, post-doctoral training in CNS/Cardiovascular pharmacology at SK&F, and Toxicology at SRI International. Jag Khalsa, MS, PhD


:: CLDF ::

chronicliverdisease.org [cached]

Jag Khalsa, PhD
Dr. Jag Khalsa, with about 50 years of experience in drug research, serves as the Chief of the Medical Consequences Branch, National Institute on Drug Abuse, NIH, DHHS; is responsible for developing/administering a national and international program of clinical research on medical and health consequences of drug abuse and co-occurring infections (HIV, HCV, and others). Prior to joining NIDA in 1987, he served for approximately 10 years as a pharmacologist/toxicologist assessing safety (carcinogenic/teratogenic) potential of chemicals [INDs/NDAs] and food additives) and clinical evaluator at the FDA. He has published in pharmacology, toxicology, epidemiology and medical journals. He serves on editorial boards of Journals of Addiction Medicine, Research on HIV/AIDS and Palliative Care, Frontiers of Neuroscience, and Clinical Infectious Diseases. He also serves on numerous Federal and NIH level committees including the HHS Viral Hepatitis Implementation Group (VHIG), National Commission on Digestive Diseases and its two sub-committees (Liver Research, Diabetes Research), Federal Task Force on TB, NIH Steering Committee on Centers for AIDS Research, and Human Microbiome Workgroup. He has received distinguished service awards from the FDA Commissioner, NIDA and NIH Directors, Society of Neuro-Immune-Pharmacology (SNIP), Life Time Achievement Awards from SNIP and International Conference on Molecular Medicine (India) and MIT, India; a commendation from the US Congress, Awards of Merit from the International Society of Addiction Medicine (ISAM), the President of the American Society of Addiction Medicine (ASAM), and a Certificate of Appreciation from the Office of Assistant Secretary for Health (Drs. Howard Koh and Ron Valdiserri), DHHS. He has a Ph.D. in neuro-psycho-pharmacology, a Master's degree in herbal pharmacology, post-doctoral training in CNS/Cardiovascular pharmacology at SK&F, and Toxicology at SRI International.


endocrine.conferenceseries.com

Dr. Jag Khalsa, with 47+ years of experience in drug research, serves as the Chief of the Medical Consequences Branch, NIDA/NIH/DHHS, is responsible for developing/administering a national and international program of clinical research on medical and health consequences of drug abuse and co-occurring infections (HIV, HCV, and others).
Prior to joining NIDA in 1987, he served for ~10 yrs as a pharmacologist/toxicologist assessing safety (carcinogenic/teratogenic) potential of chemicals [INDs/NDAs] and food additives) and clinical evaluator at FDA. He has published in pharmacology, toxicology, epidemiology and medical journals. He serves on editorial boards of Journals of Addiction Medicine, Research on HIV/AIDS and Palliative Care, Frontiers of Neuroscience, and Clinical Infectious Diseases. He has received distinguished service awards from the FDA Commissioner, NIDA and NIH Directors, SNIP, Life Time Achievement Awards, a commendation from the US Congress, and ASAM Presidential award. He has a Ph.D. in neuro-psycho-pharmacology, post-doctoral trainings in CNS/Cardiovascular pharmacology at SK&F, and Toxicology at SRI International.


Editorial Board Members | USG

blumsrewarddeficiencysyndrome.com [cached]

Dr. Jag Khalsa, with about 50 years of experience in drug research, serves as the Chief of the Medical Consequences Branch, National Institute on Drug Abuse, NIH, DHHS; is responsible for developing/administering a national and international program of clinical research on medical and health consequences of drug abuse and co-occurring infections (HIV, HCV, and others).
Prior to joining NIDA in 1987, he served for ~10 yrs as a pharmacologist/toxicologist assessing safety (carcinogenic/teratogenic) potential of chemicals [INDs/NDAs] and food additives) and clinical evaluator at FDA. He has published in pharmacology, toxicology, epidemiology and medical journals. He serves on editorial boards of Journals of Addiction Medicine, Research on HIV/AIDS and Palliative Care, Frontiers of Neuroscience, and Clinical Infectious Diseases. He also serves on numerous Federal and NIH level committees including the HHS Viral Hepatitis Implementation Group (VHIG), National Commission on Digestive Diseases and its two sub-committees (Liver Research, Diabetes Research), Federal Task Force on TB, NIH Steering Committee on Centers for AIDS Research, and Human Microbiome Workgroup. He has received distinguished service awards from the FDA Commissioner, NIDA and NIH Directors, Society of Neuro-Immune-Pharmacology (SNIP), Life Time Achievement Awards from SNIP and International Conference on Molecular Medicine (India) and MIT, India; a commendation from the US Congress, Awards of Merit from the International Society of Addiction Medicine (ISAM), the President of the American Society of Addiction Medicine (ASAM), and a Certificate of Appreciation from the Office of Assistant Secretary for Health (Drs. Howard Koh and Ron Valdiserri), DHHS. He has a PhD in neuro-psycho-pharmacology, a Master's degree in herbal pharmacology, post-doctoral training in CNS/Cardiovascular pharmacology at SK&F, and Toxicology at SRI International. Jag Khalsa, MS, PhD


www.brightice.org

Dr. Jag H. Khalsa
National Institute of Health, USA Dr. Jag Khalsa, with 47+ years of experience in drug research, serves as the Chief of the Medical Consequences Branch, NIDA/NIH/DHHS, is responsible for developing/administering a national and international program of clinical research on medical and health consequences of drug abuse and co-occurring infections (HIV, HCV, and others). Prior to joining NIDA in 1987, he served for ~10 yrs as a pharmacologist/toxicologist assessing safety (carcinogenic/teratogenic) potential of chemicals [INDs/NDAs] and food additives) and clinical evaluator at FDA. He has published in pharmacology, toxicology, epidemiology and medical journals. He serves on editorial boards of Journals of Addiction Medicine, Research on HIV/AIDS and Palliative Care, Frontiers of Neuroscience, and Clinical Infectious Diseases. He has received distinguished service awards from the FDA Commissioner, NIDA and NIH Directors, Society of Neuro-Immune-Pharmacology (SNIP), Life Time Achievement Awards from International Conference on Molecular Medicine (India) and MIT, India; a commendation from the US Congress, Awards of Merit from the International Society of Addiction Medicine (ISAM), and the President of the American Society of Addiction Medicine (ASAM). He has a Ph.D. in neuro-psycho-pharmacology, post-doctoral trainings in CNS/Cardiovascular pharmacology at SK&F, and Toxicology at SRI International. BIOGRAPHY


Similar Profiles

city

Browse ZoomInfo's Business
Contact Directory by City

city

Browse ZoomInfo's
Business People Directory

city

Browse ZoomInfo's
Advanced Company Directory